Выбор глиптинов в разных клинических ситуациях – комментарии к портретам пациентов


Л.А. Руяткина 1, М.Ю. Сорокин 2

1 ГБОУ ВПО “Новосибирский государственный медицинский университет Минздравсоцразвития”, Новосибирск; 2 Диабетологический центр МБУЗ ГКБ № 1, Новосибирск
В обзоре литературы на основе доказательной медицины рассмотрены вопросы безопасности ингибиторов дипептидилпептидазы-4 (иДПП-4) для пациентов с нарушениями функции почек и печени, а также их влияние на параметры, определяющие степень сердечно-сосудистого риска. Проведен анализ эффективности и безопасности использования иДПП-4 в комбинации с инсулинотерапией с учетом влияния на массу тела, индукцию гипогликемий и сахароснижающую эффективность.

Литература


1. Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 in-hibitor
saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled
52-week efficacy and safety study. Int J Clin Pract. 2011;65(12):1230–39.
2. Bristol-Myers Squibb. Onglyza (saxagliptin) 2,5mg & 5mg film-coated tablets. Summary of Product Characteristics last updated on the eMC: 11/01/2012. Available from: http://www.medicines.org.uk/emc/document.aspx?document id=22315&docType=SPC.
3. Lukashevich V, Schweizer A, Shao Q, et al. Safety and efficacy of vildagliptin versus placebo in patients
with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011;13(10):947–54.
4. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10(7):545–55.
5. Vaghasiya J, Sheth N, Bhalodia Y, et al. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regul Pept 2011;166(1–3): 48–54.
6. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 dia-betes. Endocr J 2011; 58(1):69–73.
7. Ligueros-Saylan M, Foley JE, Schweizer A, et al. An assessment of adverse effects of vildagliptin versus
comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab
2010;12(6):495–509.
8. Arase Y, Suzuki F, Kobayashi M, et al. Efficacy and safety in sitagliptin therapy for diabetes complicated
by chronic liver disease caused by hepatitis C virus. Hepatol Res 2011;41(6):524
9. Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: metaanalysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab
2010;12(6):485–94.
10. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a
pooled analysis of data from 10 246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7.
11. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol 2012;11:6.
12. Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis
of randomized clinical trials. Curr Med Res Opin 2011;27(Suppl. 3):57–64.
13. Merck TECOS trial: Sitagliptin Cardiovascular Outcome Study (0431-082 AM1); http://www.merck.com/
mrl/clinical_trials/outcomes_study.html; http://www.tecos-study.com/tecos/
14. Bristol-Myers Squibb, AstraZeneca. Bristol-Myers Squibb, Astra-Zeneca commence SAVORTIMI53
trial of ONGLYZA for type 2 diabetes. March 2010; (press release); http://www.newsmedical.net/news/20100310/Bristol-Myers-Squibb-AstraZeneca-commence-SAVORTIMI-53-trial-of-ONGLYZA-for-type-2-diabetes.aspx.
15. A 5-year Study to Compare the Durability of Glycemic Control of a Combination Regimen With Vildagliptin
& Metformin Versus Standard-of-care Monotherapy With Metformin, Initiated in Treatment-naïve Patients With Type 2 Diabetes Mellitus; Sponsored by Novartishttp://clinicaltrial.gov/ct2/show/NCT01528
254?term=NCT01528254&rank=1.
16. Koren S, Shemesh-Bar L, Tirosh A, et al. The Effect of Sitagliptin Versus Glibenclamide on Ar-terial Stiffness, Blood Pressure, Lipids, and Inflammation in Type 2 Diabetes Mellitus Patients. Diabetes Technol Ther. 2012 Apr 18. [Epub ahead of print].
17. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting li-pid levels: influence of normal
food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008;118(20):2047–56.
18. European Association for Cardiovascular Prevention & Rehabilitation. Reiner Z, et al. ESC/EAS Guidelines
for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Car-diology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32(14):1769–818.
19. Tremblay AJ, Lamarche B, Deacon CF, et al. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011;13(4):366–73.
20. Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabet-ic patients. J Clin Endocrinol Metab 2009;94(3):846–52.
21. Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intes-tinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49(9):2049–57.
22. Ogawa S, Ishiki M, Nako K, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011;223(2):133–35.
23. Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood
pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008;48(5):592–98.
24. Bosi E, Shao Q, Cohen E. Improved blood pressure lowering in hypertensive patients with type 2
diabetes with vildagliptin combined with metformin compared with metformin alone. Presented at ADA
Annual Meeting; June 22–26, 2007; Chicago,IL. 2165-PO.
25. Harashima SI, Ogura M, Tanaka D, et al. Sitagliptin add-on to low dosage sul-phonylureas: efficacy and
safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. Int J
Clin Pract 2012;66(5):465–76.
26. Del Guerra S, Marselli L, Lupi R, et al. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications. 2005;19(1):60–4.
27. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260–65.
28. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin
in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442–51.
29. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twicedaily
premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28: 254–59.
30. Guler S, Vaz JA, Ligthelm R. Intensification lessons with modern premixes: from clinical trial to clinical
practice. Diabetes Res Clin Pract 2008;81(Suppl. 1):23–30.
31. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(Suppl. 3):18–24.
32. Vilsboll T, Rosenstock J, Yki-Jorvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12(2):167–77.
33. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in
type 2 diabetes. Diabetologia 2007;50(6):1148–55.
34. Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as addon therapy in patients with
poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Cur Med Res Opin
2012;28(4):513–23.
35. Hollander P, Raslova K, Skjoth TV, et al. Efficacy and safety of insulin detemir once daily in combination
with sitagliptin and met-formin: the TRANSITION randomized controlled trial. Diabetes Obes Metab 2011;13(3):268–75.
36. Дедов И.И., Шестакова М.В., Александров А.А. и др. Алгоритмы специализированной помощи больным сахарным диабетом // Сахарный диабет 2011. № 3. Приложение.


Об авторах / Для корреспонденции


Руяткина Л.А. – д.м.н., профессор, ГБОУ ВПО “Новосибирский государственный медицинский университет Минздравсоцразвития”, Новосибирск
Сорокин М.Ю. – д.м.н., профессор, Диабетологический центр МБУЗ ГКБ № 1, Новосибирск


Похожие статьи


Бионика Медиа